Metastatic Triple-negative Breast Cancer
Oncology·MeSH: Triple Negative Breast Neoplasms
Prevalence
287.0 / 100K
Incidence
128.0 / 100K/yr
2 drugs in development·2 companies·2 clinical trials
Drug Pipeline by Phase
Approved(1)
| Drug | Company |
|---|---|
| trodelvy | Immunome Inc. (IMNM) |
Phase 3(1)
| Drug | Company |
|---|---|
| sacituzumab govitecan | IMMUNOMEDICS INC (IMMU) |
Compare drugs
Frequently asked questions
How many drugs are in development for Metastatic Triple-negative Breast Cancer?
BioSniper tracks 2 drugs in development for Metastatic Triple-negative Breast Cancer across 2 companies.
How many clinical trials target Metastatic Triple-negative Breast Cancer?
There are 2 clinical trials targeting Metastatic Triple-negative Breast Cancer tracked by BioSniper.
What is the prevalence of Metastatic Triple-negative Breast Cancer?
The estimated prevalence of Metastatic Triple-negative Breast Cancer is approximately 287.0 per 100,000 population.
Deep-dive into Metastatic Triple-negative Breast Cancer
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis